THE-ASAHI-GLASS-FNDN
15.6.2022 04:02:08 CEST | Business Wire | Press release
This year marks the 31st awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two winners, individuals or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors have selected the following 2022 Blue Planet Prize recipients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608006214/en/
2022 recipients
His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan
Born in the Kingdom of Bhutan, Date of Birth: 11 November, 1955
His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan, is the visionary leader who introduced the development philosophy of Gross National Happiness (GNH) which places the well being of the people at the heart of development activities and programmes. GNH gives importance to environmental conservation, sustainable and equitable development, and promotion of culture and social values which contribute to collective happiness. Using happiness as a social indicator was taken on by the United Nations and OECD also employed it in their reports, giving inspiration for an alternative paradigm to modern society.
Professor Stephen Carpenter (USA)
Born in the USA, Date of Birth: 5 July, 1952
Emeritus Director of the Center for Limnology,
Stephen Alfred Forbes Professor Emeritus of Integrative Biology, University of Wisconsin-Madison
Professor Stephen Carpenter has conducted research on lake ecosystems for more than 40 years. Through his research on lake eutrophication, from nutrients such as phosphorus and nitrogen, he studied the resilience of lakes using mathematical models, providing a new perspective on social-ecological systems. He also worked on the environmental pollution from phosphorus and nitrogen through land use, showing the critical state of the global phosphorus cycle and the need to review human activity from a broad geochemical viewpoint.
Each recipient is presented with a certificate of merit, a commemorative trophy, and 50 million Japanese yen in prize money.
We would like to hold the Blue Planet Prize Award Ceremony and commemorative lectures, which could well be on a smaller scale, while taking proper measures to prevent infection with the new coronavirus. The Award Ceremony is scheduled on Wednesday, October 5, 2022 at Tokyo Kaikan. Commemorative lectures will be given on October 6 and 8, 2022, at the University of Tokyo and at Kyoto University, respectively.
This press release and the photo of each recipient will be published 11 a.m. on Wednesday June 15 on the website of the Asahi Glass Foundation (www.af-info.or.jp/en
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608006214/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
